This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics
Organizer(s): Gary D. Wu, Scott Snapper, Judy H. Cho and Aida Habtezion
Date: January 13 - 17, 2019
Location: Sagebrush Inn & Suites, Taos, NM, USA
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Takeda Pharmaceutical Company Limited and Theravance Biopharma
Summary of Meeting:
Inflammatory bowel diseases (IBD), which afflict millions of patients, are rapidly increasing in incidence world-wide in parallel with industrialization. Pathogenesis involves both host genetic as well environmental factors, with the most currently utilized therapeutics focusing on long-term host immunosuppression. Despite tremendous advances in our understanding of IBD genetics, the mucosal immune system, and environmental factors such as the gut microbiome, currently available therapeutic modalities for IBD remain suboptimal. The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplinary discussions focused on IBD; 2) Identify both opportunities and gaps in current knowledge of the pathogenesis of IBD important for the development of new diagnostics and therapeutics; and 3) Create a multidisciplinary environment that will inspire both young and established investigators by highlighting currently available opportunities in IBD research. The anticipated outcome will be a better understanding of the advances and challenges in developing new therapies for patients with IBD.
Scholarship Deadline: October 4 2018
Discounted Abstract Deadline: October 4 2018
Abstract Deadline: October 16 2018
Discounted Registration Deadline: November 13 2018
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Boehringer Ingelheim Pharmaceuticals, Inc.Janssen R&D: Pharmaceutical Companies of Johnson & JohnsonTakeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company LimitedTheravance Biopharma
We gratefully acknowledge additional support for this conference from:
Kenneth Rainin Foundation
Keystone Symposia thanks the following Patrons for their support of $5,000 - $9,999.
Kenneth Rainin Foundation
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1 R13 DK118917-01
Funding for this conference was made possible (in part) by 1 R13 DK118917-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found